Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • Track 1-1Basis of oncogenesis
  • Track 1-2Protoncogenes formation
  • Track 1-3Metastasis
  • Track 1-4Evasion of apoptosis
  • Track 1-5Epidemiology of cancer
  • Track 1-6Cancer pathogenesis
  • Track 2-1Genomic instability
  • Track 2-2Oncogenes and protoncogenes
  • Track 2-3Tumor suppressor genes
  • Track 2-4Epigenetics
  • Track 2-5Clonal evolution
  • Track 2-6Cancer stem cells
  • Track 2-7Virology and cancer
  • Track 3-1Bioinformatics and functional analysis of oncogenes
  • Track 3-2Operomics and transcriptomics
  • Track 3-3Cancer genome sequencing
  • Track 3-4Synthetic lethality
  • Track 3-5Mutation and oncogenomics
  • Track 4-1Lung Cancer
  • Track 4-2Breast cancer
  • Track 4-3Bone Cancer
  • Track 4-4Skin Cancer
  • Track 4-5Pancreatic Cancer
  • Track 4-6Brain Cancer
  • Track 4-7Prostate cancer
  • Track 4-8Blood cancer
  • Track 4-9Liver Cancer
  • Track 4-10Colorectal Cancer
  • Track 4-11Oral Cancer
  • Track 4-12Throat Cancer
  • Track 4-13Thyroid Cancer
  • Track 4-14Cervical Cancer
  • Track 4-15Ovarian Cancer
  • Track 4-16Occular Cancer
  • Track 4-17Kidney Cancer
  • Track 5-1Inheritable genes and cancer
  • Track 5-2Mechanism of inheritable cancer
  • Track 5-3Hereditary breast and ovarian cancer
  • Track 5-4Hereditary Non Polypsis Colorectal cancer
  • Track 5-5Li Fraumeni syndrome
  • Track 5-6Familial Polypsis
  • Track 5-7DNA repair defects and increased cancer risks
  • Track 5-8Retinoblastoma
  • Track 6-1Mechanisms of cancer epigenetics
  • Track 6-2Micro RNA and DNA repair
  • Track 6-3Epigenetic carcinogens
  • Track 6-4Prognosis and treatment
  • Track 6-5Pathophysiology
  • Track 7-1Metastatic symptoms
  • Track 7-2Multimodal therapies
  • Track 7-3Pathophysiology
  • Track 7-4Routes of metastasis
  • Track 7-5Diagnosis and management
  • Track 8-1Tumor targeting strategies
  • Track 8-2Hormonal and biological agents
  • Track 8-3Cancer drug targets
  • Track 8-4Cliical trials
  • Track 8-5Anticancer therapeutics
  • Track 8-6Research and analytical methods
  • Track 9-1Malignant transformation of cells
  • Track 9-2DNA alterations
  • Track 9-3Tumor antigens
  • Track 9-4Immunologic pathway involving tumor eradication
  • Track 9-5Cancer immunoediting
  • Track 10-1Genomic modification
  • Track 10-2Genome atlas(TCGA)
  • Track 10-3Cancer pharmacogenomics
  • Track 10-4Metabolomic tehnologies
  • Track 10-5Diagnostic tools
  • Track 10-6Metabolomics as biomarker
  • Track 11-1Chemotherapy
  • Track 11-2Radiation therapy
  • Track 11-3Surgical therapy
  • Track 11-4Immunotherapy
  • Track 11-5Alternative medicine
  • Track 11-6Stem cell therapy
  • Track 11-7Bone marrow transplantation
  • Track 11-8Hormone replacement therapy
  • Track 11-9Molecular targeted therapies
  • Track 11-10Gene therapy
  • Track 12-1Metastasis in CNS
  • Track 12-2Blood brain barrier disruption
  • Track 12-3Peritumoral factors
  • Track 12-4Diagnostic procedures
  • Track 13-1Imaging biomarker
  • Track 13-2Clinical biomarker
  • Track 13-3Genetic biomarker
  • Track 13-4Predictive biomarker
  • Track 13-5Molecular biomarker
  • Track 13-6Cell free biomarker
  • Track 14-1Nanothearanostics
  • Track 14-2Nano vectors
  • Track 14-3Nano sensors
  • Track 14-4Nano medicine
  • Track 14-5Nano cubes
  • Track 14-6Nano bullets
  • Track 14-7Nanotechnology in cancer therapy
  • Track 15-1Genomic mutation
  • Track 15-2Molecular diagnostics
  • Track 15-3Non genetic characteristics
  • Track 15-4Targeted drug therapies
  • Track 15-5Clinical trials of personalized medicine
  • Track 16-1Autologous stem cell transplants
  • Track 16-2Tandem stem cell transplants
  • Track 16-3Allogenic stem cell transplants
  • Track 16-4Non myeloablative stem cell transplants
  • Track 16-5Syngenic stem cell transplants
  • Track 16-6Side effects
  • Track 16-7Dietary needs
  • Track 17-1Lifestyle changes
  • Track 17-2Diet and cancer
  • Track 17-3Vaccinations
  • Track 17-4Natural therapy
  • Track 17-5Physiological and social aspects
  • Track 18-1Technologies of screening
  • Track 18-2Types of cancer screening by condition
  • Track 18-3Risks of screening
  • Track 19-1Yoga and meditation
  • Track 19-2Integrative medicine
  • Track 19-3Herbal remedies and dietary supplements
  • Track 19-4Acupuncture
  • Track 19-5Gerson therapy
  • Track 20-1Areas of research
  • Track 20-2Flaws and vulnerabilities
  • Track 20-3Distributed computing
  • Track 20-4Organizations
  • Track 21-1MRI vs CT
  • Track 21-2Magnetic Resonance Imaging
  • Track 21-3Nuclear Medical Imaging
  • Track 21-4X ray Medical Imaging
  • Track 21-5Applications of Imaging
  • Track 21-6Optical Imaging
  • Track 21-7Multi Modal Imaging
  • Track 21-8Ultrasonography
  • Track 21-9Clinical Imaging
  • Track 22-1Clinical pharmacology
  • Track 22-2Neuropharmacology
  • Track 22-3Psychopharmacology
  • Track 22-4Cardiovascular pharmacology
  • Track 22-5Theoretical pharmacology
  • Track 22-6Dental pharmacology
  • Track 23-1Drug-metabolizing enzymes
  • Track 23-2Drug labeling
  • Track 23-3Polypharmacy
  • Track 23-4Predictive prescribing
  • Track 24-1Issues in phytotherapy
  • Track 24-2Constituents and drug synergism
  • Track 24-3Herb and drug interactions
  • Track 25-1Molecular profiling techniques
  • Track 25-2New biologics and vaccines
  • Track 25-3Chemical proteomics
  • Track 25-4Combination strategies in immuno-oncology
  • Track 25-5Novel biomarker discovery
  • Track 25-6Cancer epigenetics